Novo Nordisk GBS and MAHE to advance pharmacometrics research and talent development in India

image credit- freepik

Bengaluru-based Novo Nordisk Global Business Services (GBS) and the Manipal Academy of Higher Education (MAHE) have expanded their long-standing collaboration to strengthen India's capabilities in pharmacometrics, a specialised scientific discipline that uses data, modelling and simulation to support drug development and clinical decision-making.

As part of this collaboration, Novo Nordisk GBS is set to provide financial support of Rs 1.75 crore over five years to support the growing need for specialised talent, research capacity and advanced infrastructure in quantitative drug development.

As medicines become increasingly complex and data-driven, pharmacometrics is playing a critical role in improving clinical trial design, understanding treatment responses across patient populations and supporting more informed drug development decisions.

A key focus of the collaboration will be the establishment of an advanced pharmacometrics computing facility at MAHE, aimed at supporting research, training and scientific collaboration in the field.

The initiative will also support one full-time PhD scholar and one post-doctoral fellow annually, helping create a specialised talent pipeline for quantitative drug development and clinical pharmacology.

In addition, four to six specialised learning modules will be introduced under the theme Innovation for Quantitative Drug Development. These modules will cover areas such as Model-Informed Drug Development (MIDD), systems modelling approaches and translational frameworks for emerging therapeutic modalities, including cell and gene therapies and multi-specific therapies.

The collaboration seeks to create greater opportunities for researchers and students to engage with real-world drug development challenges while strengthening India's participation in a field that is becoming increasingly important to global pharmaceutical innovation.